Updated results of the phase I CheckMate-016 trial include findings for the Opdivo (sunitinib) and Yervoy (pazopanib) combinations showed the overall response rate (ORR; secondary endpoint) was 40.4% (n=47) in both arms.
People with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes, according to research from City of Hope.
